Role of Delta Opioid Receptors in Bone Cancer
Bone cancer pain is one of the more common and challenging symptoms associated with advanced cancer. Current treatments for bone cancer pain are limited due to lack of efficacy, side effects and/or difficulty in administration. Previous work in the Bilsky laboratory provides a rationale for developing analgesics (pain relievers) that target the delta opioid receptor. The research funded by the Maine Cancer Foundation will investigate the activity and side-effect profile of novel drugs that activate this receptor in a mouse model of bone cancer, with the ultimate goal of having better analgesics for bone cancer patients (as well as other cancer-related pain conditions).